Literature DB >> 21239715

Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10.

Angeles Domínguez-Soto1, Elena Sierra-Filardi, Amaya Puig-Kröger, Blanca Pérez-Maceda, Fernando Gómez-Aguado, María Teresa Corcuera, Paloma Sánchez-Mateos, Angel L Corbí.   

Abstract

Dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN; CD209) is a human pathogen-attachment C-type lectin with no obvious murine ortholog and for which ligation leads to enhanced anti-inflammatory cytokine release and altered proinflammatory cytokine production. Although induced by IL-4 in monocytes and considered as a DC marker, DC-SIGN expression on human APCs under homeostatic conditions is so far unexplained. We report in this study that M-CSF enhances DC-SIGN expression on in vitro derived anti-inflammatory macrophages and that M-CSF mediates the induction of DC-SIGN by fibroblast- and tumor cell-conditioned media. The M-CSF-inducible DC-SIGN expression along monocyte-to-macrophage differentiation is dependent on JNK and STAT3 activation, potentiated by STAT3-activating cytokines (IL-6, IL-10), and abrogated by the M1-polarizing cytokine GM-CSF. In pathological settings, DC-SIGN expression is detected in tumor tissues and on ex vivo-isolated CD14(+) CD163(+) IL-10-producing tumor-associated macrophages. Importantly, DC-SIGN Abs reduced the release of IL-10 from macrophages exposed to Lewis(x)-expressing SKBR3 tumor cells. These results indicate that DC-SIGN is expressed on both wound-healing (IL-4-dependent) and regulatory (M-CSF-dependent) alternative (M2) macrophages and that DC-SIGN expression on tumor-associated macrophages might help tumor progression by contributing to the maintenance of an immunosuppressive environment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239715     DOI: 10.4049/jimmunol.1000475

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.

Authors:  Rada Amin; Frédéric Mourcin; Fabrice Uhel; Céline Pangault; Philippe Ruminy; Loic Dupré; Marion Guirriec; Tony Marchand; Thierry Fest; Thierry Lamy; Karin Tarte
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

2.  Envelope Protein Glycosylation Mediates Zika Virus Pathogenesis.

Authors:  Derek L Carbaugh; Ralph S Baric; Helen M Lazear
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

3.  Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Authors:  Lisa K Spary; Josephine Salimu; Jason P Webber; Aled Clayton; Malcolm D Mason; Zsuzsanna Tabi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

4.  Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor.

Authors:  Po-Lin Kuo; Ming-Shyan Huang; Da-En Cheng; Jen-Yu Hung; Chih-Jen Yang; Shah-Hwa Chou
Journal:  J Biol Chem       Date:  2012-01-30       Impact factor: 5.157

5.  DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance.

Authors:  Patricia Conde; Mercedes Rodriguez; William van der Touw; Ana Jimenez; Matthew Burns; Jennifer Miller; Manisha Brahmachary; Hui-ming Chen; Peter Boros; Francisco Rausell-Palamos; Tae Jin Yun; Paloma Riquelme; Alberto Rastrojo; Begoña Aguado; Joan Stein-Streilein; Masato Tanaka; Lan Zhou; Junfeng Zhang; Todd L Lowary; Florent Ginhoux; Chae Gyu Park; Cheolho Cheong; Joshua Brody; Shannon J Turley; Sergio A Lira; Vincenzo Bronte; Siamon Gordon; Peter S Heeger; Miriam Merad; James Hutchinson; Shu-Hsia Chen; Jordi Ochando
Journal:  Immunity       Date:  2015-06-09       Impact factor: 31.745

Review 6.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

7.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Authors:  Hui-Ming Chen; William van der Touw; Yuan Shuo Wang; Kyeongah Kang; Sunny Mai; Jilu Zhang; Dayanira Alsina-Beauchamp; James A Duty; Sathish Kumar Mungamuri; Bin Zhang; Thomas Moran; Richard Flavell; Stuart Aaronson; Hong-Ming Hu; Hisashi Arase; Suresh Ramanathan; Raja Flores; Ping-Ying Pan; Shu-Hsia Chen
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

8.  Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.

Authors:  Francis Mussai; Carmela De Santo; Issa Abu-Dayyeh; Sarah Booth; Lynn Quek; Rosanna M McEwen-Smith; Amrana Qureshi; Francesco Dazzi; Paresh Vyas; Vincenzo Cerundolo
Journal:  Blood       Date:  2013-06-03       Impact factor: 22.113

Review 9.  Targeting the C-type lectins-mediated host-pathogen interactions with dextran.

Authors:  Sergey Pustylnikov; Divya Sagar; Pooja Jain; Zafar K Khan
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

10.  Effective Predictor of Colorectal Cancer Survival Based on Exclusive Expression Pattern Among Different Immune Cell Infiltration.

Authors:  Xiaowen Xu; Jun Ma; Guanyu Yu; Qun Qiu; Wei Zhang; Fuao Cao
Journal:  J Histochem Cytochem       Date:  2021-02-06       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.